Followers | 129 |
Posts | 2150 |
Boards Moderated | 1 |
Alias Born | 12/27/2007 |
Tuesday, March 14, 2017 1:23:12 PM
This Stock is so terrible undervalued.....
Market-Cap: c$20.5 Million (US$15.15 Million)
Cash: c$5.1 Million << enough untill mid 2018
Price: $0.22
AQS1301 topline results in 1Q 2017
File for CDN approval of Topiramate XR in 1H 2017
File for CDN approval of Oxcarbazepine XR in 1H 2017
Additional Product acquisitions in 2017
Partnership for AQS1301 in 2017
Operational profitability estimated in 2017
Two products launches to date (Tacrolimus IR and Vistitan™)
3 long-acting, transdermal programs in development, on track to file NDA in 2018
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM